Amifena (mefenamic acid) coated tablets 500 mg. №20

$12.00

Manufacturer: Ukraine

Acute respiratory viral infections and influenza.

Pain of low and moderate intensity: muscular, articular, traumatic, toothache, headache of various etiologies, postoperative and postpartum pain.

primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, in the absence of pathology of the pelvic organs.

Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis.

Category:

Description

Ingredients

active ingredient: mefenamic acid;

1 tablet contains mefenamic acid 500 mg;

excipients: lactose, microcrystalline cellulose, sodium lauryl sulfate, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, talc, hypromellose (hydroxypropyl methylcellulose), polyethylene glycol, titanium dioxide (E 171).

Dosage form

Film-coated tablets.

Basic physical and chemical properties: oblong (for a dosage of 500 mg) tablets with a biconvex surface, film-coated, white.

Pharmacotherapeutic group

Non-steroidal anti-inflammatory drugs. Fenamates. mefenamic acid. ATX code M01A G01.

Pharmacodynamics

Mefenamic acid is an NSAID that has anti-inflammatory, analgesic, and antipyretic effects.

Prostaglandins are involved in a number of pathological processes, including inflammation, modulation of the pain response, dysmenorrhea, menorrhagia, and hyperthermia. Like most non-steroidal anti-inflammatory drugs, mefenamic acid inhibits prostaglandin synthetases (COX (COX)), which leads to a slowdown in the synthesis of prostaglandins and a decrease in their levels. There is evidence that fenamates inhibit the action of already synthesized prostaglandins. Mefenamic acid is able to suppress the synthesis of other inflammatory mediators (serotonin, kinins, etc.), reduce the activity of lysosomal enzymes involved in the inflammatory response. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in the focus of inflammation, increases cell resistance and stimulates wound healing. In the mechanism of analgesic action, a significant role is played by the local effect of mefenamic acid on the site of inflammation and its ability to inhibit the formation of algogens (kinins, histamine, serotonin), along with the effect on the central mechanisms of pain sensitivity. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the center of thermoregulation. Mefenamic acid stimulates the formation of interferon. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the center of thermoregulation. Mefenamic acid stimulates the formation of interferon. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the center of thermoregulation. Mefenamic acid stimulates the formation of interferon.

Indications

  • Acute respiratory viral infections and influenza.
  • Pain of low and moderate intensity: muscular, articular, traumatic, toothache, headache of various etiologies, postoperative and postpartum pain.
  • Primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, in the absence of pathology of the pelvic organs.
  • Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis.

Contraindications

Hypersensitivity to mefenamic acid or to any other component of the drug.

Due to the risk of cross-sensitivity, mefenamic acid should not be used in patients who have previously experienced hypersensitivity reactions (for example, bronchial asthma, bronchospasm, rhinitis, angioedema, or urticaria) after taking acetylsalicylic acid (aspirin), ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs) .

Inflammatory bowel disease.

History of gastrointestinal bleeding or perforation associated with prior NSAID therapy.

History of active or recurrent ulcer/bleeding (two or more separate confirmed cases of ulcer or bleeding).

Severe heart failure.

Diseases of the hematopoietic organs.

Severe hepatic or renal insufficiency .

Treatment of pain after coronary artery bypass grafting.

Simultaneous administration of specific inhibitors of cyclooxygenase-2 (COX-2).

Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome.

During pregnancy and breastfeeding.

Age up to 5 years.

Directions

Use the drug should be under the supervision of a physician, determines the dose and duration of treatment. Side effects of mefenamic acid can be minimized by using the minimum effective dose of the drug for a short period.

The drug is intended for oral use. The drug should be taken during or after a meal.

Adults and children over 12 years old

250-500 mg 3-4 times a day.

According to the indications and with good tolerance, the dose can be increased to a maximum of 3000 mg. After achieving a therapeutic effect, the dose should be reduced to 1000 mg per day.

Children aged 5 to 12

250 mg 3-4 times a day.

Elderly patients (from 65 years old)

Dose adjustment is not required (see Section “Peculiarities of use”).

Exceed the recommended dose.

In the treatment of pain syndrome, the course of treatment lasts up to 7 days.

With dysmenorrhea, the drug should be used from the first day of menstrual pain. The duration of the drug is determined by the doctor.

With menorrhagia, the drug should be used from the first day of heavy bleeding. The duration of the drug is determined by the doctor.

The course of treatment for diseases of the joints can last from 20 days to 2 months or more.